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Obesity is associated with a chronic low-grade inflammatory state that drives the
 development of obesity-related co-morbidities such as insulin resistance/type 2 diabetes, 
non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease. This metabolic
inflammation is thought to originate in the adipose tissue, which becomes inflamed and 
insulin resistant when it is no longer able to expand in response to excess caloric and
nutrient intake. The production of inflammatory mediators by dysfunctional adipose tissue 
is thought to drive the development of more complex forms of disease such as type 2
diabetes and NAFLD. An important factor that may contribute to metabolic inflammation 
is the cytokine macrophage migration inhibitory factor (MIF). Increasing evidence suggests 
that MIF is released by adipose tissue in obesity and that it is also involved in metabolic 
and inflammatory processes that underlie the development of obesity-related pathologies. 
This review provides a comprehensive summary of our current knowledge on the role of 
MIF in obesity, its production by adipose tissue, and its involvement in the development of 
insulin resistance, type 2 diabetes, and NAFLD. We discuss the main findings from recent 
clinical studies in obese subjects and weight-loss intervention studies as well as results 
from clinical studies in patients with insulin resistance and type 2 diabetes. Furthermore, 
we summarize findings from experimental disease models studying the contribution of
MIF in obesity and insulin resistance, type 2 diabetes, and hepatic lipid accumulation and 
fibrosis. Although many of the findings support a pro-inflammatory role of MIF in disease 
development, recent reports also provide indications that MIF may exert protective effects 
under certain conditions.
 
 
 
 
 
Keywords: MiF, obesity, adipose tissue, insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease
Abbreviations: ALAT, alanine transaminase; ASAT, aspartate transaminase; HFD, high-fat diet; HOMA, homeo-
static model assessment; ipGTT, intraperitoneal glucose tolerance test; ipITT, intraperitoneal insulin tolerance 
test; MCD, methionine and choline deficient; MIF, macrophage migration inhibitory factor; MNC, mononuclear 
cell; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; T2D, type 2 diabetes.
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introduction
The development of obesity-associated co-morbidities such as type 
2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), and 
cardiovascular disease (CVD) is considered to be driven by the 
chronic low-grade inflammatory state that characterizes obesity (1). 
During obesity, excess caloric and nutrient intake, i.e., metabolic 
overload, leads to adipose tissue expansion and visceral adiposity. 
When the maximal expandability of an adipose tissue depot is 
reached (when adipocytes have maximally expanded) this leads 
to adipose tissue dysfunction and infiltration of immune cells, 
which is associated with insulin resistance of the adipose tissue 
itself (2, 3). Furthermore, adipocytes and infiltrated immune cells 
of this inflamed adipose tissue produce inflammatory mediators 
that can be released into the circulation (4). Thus, the adipose tissue 
becomes a source of inflammation that can drive pathogenesis in 
other tissues, leading to the development of T2D, NAFLD, and 
CVD (Figure 1).
Macrophage migration inhibitory factor (MIF) is a cytokine 
that is ubiquitously expressed, both by immune and non-immune 
cells. It is well known for its pro-inflammatory effects and is 
recognized as a negative regulator of the immunosuppressive 
actions of glucocorticoids (5). In line with this, MIF has been 
implicated in the development of many acute inflammatory and 
auto-immune diseases (6, 7), as well as chronic inflammatory 
FiguRe 1 | in obesity, adipose tissue can become a source of 
inflammation that drives disease development in distant organs. Caloric 
and nutrient excess, i.e., metabolic overload, leads to expansion of adipose 
tissue depots (expansion phase). When the maximal expandability of an adipose 
tissue depot is reached due to prolonged metabolic overload, the adipose 
tissue becomes dysfunctional, is infiltrated by immune cells, and becomes 
insulin resistant. Adipocytes and infiltrated immune cells produce inflammatory 
mediators that spill over into the circulation (spillover phase) where they drive the 
progression of obesity-related co-morbidities in distant organs, such as type 2 
diabetes, non-alcoholic fatty liver disease, and atherosclerosis.
metabolic disorders (8–10). MIF can act via its receptor CD74 
(11), and controls the recruitment of inflammatory cells via 
CXCR2 and CXCR4 signaling (8). Furthermore, MIF can exert 
pro-inflammatory effects through its enzymatic tautomerase 
and oxidoreductase activity (12, 13). Several lines of evidence 
provide indications that MIF, besides regulating inflammation, 
may also be linked to energy metabolism. It is expressed in 
metabolically active tissues such as the adipose tissue and the 
liver (9, 14). Its expression by adipocytes is regulated by glucose 
and insulin (15) and it has been shown to have catabolic effects 
in muscle (16). Furthermore, it co-localizes with insulin within 
the secretory granules of pancreatic beta cells and is a modulator 
of insulin release (17). Increasing evidence suggests that MIF 
may also control inflammatory and metabolic processes in 
the pathogenesis of obesity and associated disorders including 
insulin resistance, T2D, and NAFLD. Here, we provide a com-
prehensive review of the current knowledge on the role of MIF 
in obesity, MIF production by adipose tissue, and its role in the 
development of insulin resistance, type 2 diabetes, and NAFLD. 
Since epidemiological studies have shown both insulin resistance 
(18, 19) and NAFLD (20, 21) to be associated with future CVD 
risk, this may also have relevance for the role of MIF in vascular 
disease, which has been described elsewhere for rodents (22, 
23) and humans (24, 25), and will not be addressed here. This 
survey aims to advance our understanding on the functions of 
Table 1 | Relationship between (circulating) MiF and obesity and effects of weight loss thereupon.
Subjects bMi gender MiF (ng/ml) effect observed Reference
M F
Lean 22.6 26 14 1.2 Positive correlation plasma MIF with BMI. MNC MIF mRNA increased in 
obesity and positively correlated with BMI.
(26)
Obese 37.5 19 21 2.8
Lean 22.6 – 16 1.3 Positive correlation plasma MIF with HOMA and BMI (p = 0.10). MNC MIF 
mRNA increased in obesity and positively correlated with BMI.
(27)
Obese 40.0 – 16 3.3
Lean 20.6 – 20 0.5 Plasma MIF increased in obesity. (30)
Obese 35.2 – 26 1.9
Lean 22.1 – 6 5 Plasma MIF positively correlated with % body fat, % truncal fat, and 
fasting insulin.
(31)
Obese 35.8 – 6 16
Lean boys 16.0 59 – 3.8 Plasma MIF higher in obese boys than in overweight boys. No effect in 
girls (population: pre-pubertal schoolchildren between 5 and 13 years, 
average 9 years).
(32)
Overweight boys 22.0 32 – 3.6
Obese boys 25.7 70 – 4.2
Lean girls 15.1 – 46 3.9
Overweight girls 21.3 – 28 3.9
Obese girls 25.1 – 70 4.3
Waist circumference  
<90th percentile
20.7 41 – Median 0.6 Positive correlation plasma MIF with weight, BMI, and waist 
circumference (population: Caucasian adolescents 13–17 years).
(33)
Waist circumference  
>90th percentile
31.9 38 – Median 1.0
Healthy controls 20.2 52 32 1.0 Plasma MIF increased in metabolic syndrome. No significant correlation 
with BMI.
(34)
Metabolic syndrome 27.2 62 26 1.4
Lean 23.0 – 14 12.0 No difference in plasma MIF between lean and obese subjects. (35)
Obese 32.7 – 33 13.5
Lean <27 – ns nd MIF secretion from isolated (subcutaneous and omental) adipocytes is 
positively correlated with BMI. No difference between depots.
(38)
Obese 37 – ns nd
Lean 23.1 9 – nd Subcutaneous abdominal adipose tissue MIF mRNA expression is 
increased in obesity and is positively correlated with waist circumference.
(39)
Obese 34.7 9 – nd
Overweight 29.3 – 17 nd MIF mRNA expression in visceral adipose tissue twofold higher than in 
subcutaneous adipose tissue, and positively correlated with % body fat.
(40)
Obese 36 18 16 ns Subcutaneous abdominal adipocyte MIF mRNA expression positively 
correlated with adipocyte diameter but not with plasma MIF.
(43)
Lean 24.2 21 4 Median 5.1 Plasma MIF higher in obese than in lean subjects. Weight loss (by diet 
and physical activity based weight management program) reduced 
plasma MIF levels.
(28)
Obese before weight loss 43.0 23 48 Median 8.4
Obese after weight loss 38.3 Median 5.1
Lean 19.9 – 10 5.0 Plasma MIF and mononuclear cell MIF mRNA are higher in obese 
subjects than in lean subjects and both are reduced by weight loss (12-
week caloric restriction and light exercise-based weight loss program). 
Mononuclear cell MIF mRNA positively correlated with BMI.
(29)
Obese before weight loss 32.5 – 21 16.0
Obese after weight loss 30.6 5.4
Before intervention 27.6 nd Weight loss did not affect subcutaneous adipose tissue MIF mRNA 
expression.
(44)
Control 27.3 5 6
Caloric restriction 25.0 6 6
Caloric restriction + exercise 24.8 5 7
Obese before surgery 44.6 5 29 0.2 Serum MIF reduced 12 months after bariatric surgery. Positive 
correlation between reduction in serum MIF and body weight loss.
(45)
Obese after weight loss 35.2 0.02
Obese before surgery 46.7 5 22 0.2 Plasma MIF levels increased after weight loss (at 24 months after 
bariatric surgery).
(46)
Obese after weight loss 33.0 0.7
ns, not specified; nd, not determined.
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MIF in non-pathological and pathological processes connected 
to obesity and glucose homeostasis, with particular emphasis on 
adipose tissue and liver.
All values are mean ± SEM. Where the original article stated 
mean ± SD, SEM was calculated from SD by dividing SD by the 
square root of n.
Human Studies
Circulating MiF and Obesity
Several studies provide evidence for a positive association between 
obesity and circulating MIF levels (Table  1). Dandona and co-
workers (26) reported that obese individuals (BMI 37.5 ± 4.9 kg/m2) 
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had significantly higher plasma MIF levels (2.8 ± 2.0 ng/ml) than 
lean individuals (BMI 22.6 ± 3.4 kg/m2; plasma MIF 1.2 ± 0.6 ng/
ml) and that there was a highly significant positive correlation 
between MIF levels and BMI. Results from another study by the 
same group (27) confirmed these results, reporting MIF levels of 
3.3 ± 2.4 ng/ml in obese subjects (BMI 40.0 ± 4.4 kg/m2), which 
were significantly higher than the 1.3 ± 0.8 ng/ml observed in the 
lean controls (BMI 22.6 ±  1.9 kg/m2). Again, there was a posi-
tive correlation (p = 0.10) between MIF levels and BMI. Others 
have reported similar findings of increased circulating MIF in 
obese individuals compared with healthy lean controls (28–31), 
and showed associations with % body fat and % truncal fat (31). 
Studies in pre-pubescent schoolchildren (age 5–13 years) and male 
adolescents (age 13–17 years) demonstrate that these associations 
are not only observed in adults, reporting increased MIF levels in 
overweight and obesity in childhood and adolescence (32, 33), and 
showing positive correlations with waist circumference and BMI 
(33) in this study population as well.
A study by Kim et al. (34) compared healthy Korean subjects 
(BMI 20.2  kg/m2) without metabolic syndrome with patients 
with metabolic syndrome (BMI 27.2  kg/m2) and found higher 
levels in patients than controls (1.4 ± 0.1 and 1.0 ± 0.1 ng/ml, 
respectively), which was significant in women but not in men. 
N.B. there was no correlation between circulating MIF and BMI 
in this study, suggesting that other MIF-inducing factors play a 
role when overweight/obesity progresses toward a phenotype of 
metabolic disease.
Of note, plasma MIF concentrations tend to be higher in 
males than in females (26, 34), suggesting an inducing effect 
of male sex hormones. Indeed, circulating MIF levels are two 
to threefold higher in women with polycystic ovary syndrome 
(PCOS), an endocrine disorder characterized by elevated levels of 
androgens (31, 35). Within PCOS patients, the effect of obesity is 
not  significant due to large variation within this population, and 
comparable plasma MIF levels were found in non-obese and obese 
patients [~35 and ~55 ng/ml, respectively, in Ref. (31); 35.2 and 
48.6 ng/ml, respectively, in Ref. (35)].
Remarkably, there is a large variation in the absolute circulat-
ing MIF values in documented obesity studies, indicating that 
there may be underlying methodological differences causing 
these diverse values. A part of the variation may be explained by 
different analytical methods (e.g., different ELISA kits, multiplex 
technology) but even studies employing the same analytical tools 
report substantial differences [e.g., Ref. (26, 31)]. Hence, other 
technical or methodological issues may be responsible for these 
discrepancies. The MIF molecule itself and its oligomers are 
very hydrophobic (36, 37) and tend to precipitate or stick to 
plastic material and differences in sample preparation and/or 
pipetting can result in differences as reported in the human 
studies. Therefore, it is difficult to make comparisons between 
different studies. However, the direction of the effect (obese 
higher than lean) is mostly consistent and overall, these studies 
demonstrate a well-established association between obesity and 
circulating MIF that seems to transcend differences in age, sex, 
and ethnicity. The observed positive correlations with BMI and 
% body fat provide indication that the observed association may 
be related to the increased adipose tissue mass that is inherent 
to obesity and hint at the adipose tissue as a contributor to the 
observed association.
adipose Tissue MiF Production
Several groups have investigated adipose tissue as a potential 
source of circulating MIF in obesity (Table  1). Skurk and co-
workers (38) demonstrated that primary human pre-adipocytes 
and mature adipocytes have the capacity to produce and secrete 
MIF and the secretion of MIF was found to increase in parallel 
with the (in vitro) differentiation of pre-adipocytes. There was a 
close positive correlation between MIF release from mature adi-
pocytes and donor BMI, which was observed in both visceral and 
omental adipocytes, with no differences between these two depots. 
Others have shown similar effects on the gene expression level. 
González-Muniesa and colleagues (39) showed that MIF mRNA 
expression in subcutaneous abdominal adipose tissue is increased 
in obese individuals and correlates with waist circumference. A 
positive correlation was also reported by Alvehus and co-workers 
(40) for the visceral adipose tissue depot, which is an important 
source of inflammation and, in contrast to subcutaneous adipose 
tissue, is associated with inflammatory metabolic disorders such 
as NAFLD and CVD (41, 42). Alvehus et al. (40) showed that MIF 
mRNA expression in the visceral adipose tissue was higher than 
in the subcutaneous adipose tissue (~2-fold) and was positively 
correlated with body fat percentage. Adipose tissue inflammation 
is considered to be a consequence of adipocyte hypertrophy and 
is thought to be triggered by maximal expansion of adipocytes (2, 
3). In line with this notion, subcutaneous abdominal adipocyte 
diameter correlates with MIF mRNA expression (43).
If indeed the increased levels of circulating MIF in obesity are 
primarily the result of increased adipose tissue mass and  adipocyte 
expansion, one would logically expect plasma MIF levels to 
decrease when obese subjects lose weight. Indeed, reduced MIF 
levels have been reported upon weight loss. Church and colleagues 
(28), for instance, observed significant reductions in plasma MIF 
levels in obese individuals after a diet and physical activity based 
weight-loss program. Participants’ BMI after this 8.5-month 
program was reduced from 43.0  ±  8.6 to 38.3  ±  7.6  kg/m2  
(reflecting an average weight loss of 14.4 kg), which resulted in 
completely normalized plasma MIF levels comparable to those 
of lean controls (from median 8.4 to 5.1 ng/ml). Similar results 
were reported in a different study on the effects of weight loss 
(29) in which obese subjects participated in a 3.5-month diet 
and light exercise-induced weight-loss program. A reduction 
in BMI from 32.5 ± 1.2 to BMI 30.6 ± 1.6 kg/m2 (reflecting a 
weight loss of 4.0 ± 0.4 kg) was accompanied by a reduction in 
serum MIF from 16.0 ± 4.0 to 5.4 ± 0.4 ng/ml, which again was 
comparable to lean control subjects. Remarkably, the observed 
weight loss in both these studies in obese subjects resulted in 
completely normalized MIF levels comparable to those observed 
in lean subjects, even though BMI was still considerably higher 
in the obese subjects (and subjects were still obese even after 
weight loss), thus indicating that other factors rather than fat mass 
per se (e.g., insulin sensitivity, hormonal changes) may determine 
circulating MIF levels, or that weight loss may normalize the state 
of a particular adipose tissue depot that is primarily responsible 
for MIF production and secretion. Furthermore, a relatively small 
Table 2 | Relationship between (plasma) MiF and insulin resistance/T2D.
Subjects gender MiF (ng/ml) effect observed Reference
M F
Healthy controls 53 26 5.2 Serum MIF higher in T2D than in controls. (47)
T2D 53 26 20.7
Healthy controls 30 2.1 Plasma MIF higher in T2D than in healthy controls. (48)
T2D 46 2.6
Healthy controls 23 59 0.05 Serum MIF higher in T2D than in healthy controls, in both males and females. (49)
T2D 27 46 0.2
Normoglycemic controls 137 99 Median 4.97 Positive association plasma MIF with impaired glucose tolerance and T2D 
independent of plasma CRP and IL-6.
(50)
Impaired glucose tolerance 130 112 Median 7.95
T2D 137 107 Median 10.96
Non-diabetic Caucasians 24 <5.0 in 100% Plasma MIF higher in Pima Indians and associated with insulin resistance. (51)
Non-diabetic Pima Indians 28 >5.0 in 39%
Non-case controls 859 773 Median 17.7 Baseline MIF concentrations higher in subjects that develop T2D than in 
non-case controls. Women with MIF genotype rs1007888CC have increased 
risk of T2D.
(52)
Cases (incident T2D) 293 209 Median 18.5
Turkish adults 1093 1157 nd In men, MIF genotype rs755622GC associated with baseline diabetes, and 
C-allele carriage tends to predict new-onset diabetes. No effect in women.
(53)
Healthy pregnant controls – 40 5.3 Serum MIF higher in women with gestational diabetes. (54)
Gestational diabetes – 43 11.3
Healthy pregnant controls – 169 nd MIF genotype rs1007888GG more common in gestational diabetes. GG 
genotype significantly associated with pre-pregnancy obesity and family history 
of diabetes, and twofold more frequent in women with metabolic syndrome.
(55)
Gestational diabetes – 147 nd
nd, not determined.
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reduction in adipocyte size may already be sufficient to prevent 
further adipocyte damage and thereby attenuate the inflammatory 
process in adipose tissue.
Only a few studies have examined whether a specific adipose 
tissue depot is responsible for the release of MIF into the circula-
tion. Support for the view that circulating MIF must be produced 
by adipose tissue depots other than the subcutaneous adipose 
tissue comes from studies by Koska et al. (43) who showed that 
subcutaneous adipose tissue MIF mRNA does not correlate with 
circulating MIF levels, and Tam et al. (44) who found no effect of 
weight loss on subcutaneous adipose tissue MIF mRNA expression. 
Identification of the underlying factors that determine circulating 
MIF in obesity warrants further investigation.
Two studies on the effects of bariatric surgery-induced weight loss 
in morbidly obese subjects report conflicting results in this specific 
population. Fenske et al. (45) showed that weight loss at 12 months 
after bariatric surgery (BMI from 44.6 ± 0.9 to 35.2 kg/m2) resulted 
in reductions in serum MIF levels from 0.2 ng/ml before surgery to 
0.02 ng/ml at 12 months after surgery. Van Dielen and colleagues 
(46), on the other hand, reported similarly low-plasma MIF levels 
in  morbidly obese subjects before surgery (BMI 46.7 ± 1.1 kg/m2, 
plasma MIF 0.2  ng/ml) but observed increased MIF levels at 
24 months after bariatric surgery (weight loss to BMI 33.0 ± 0.9 kg/
m2, plasma MIF 0.7 ng/ml). To gain insight into the processes that 
determine  circulating MIF levels in these patients, longitudinal 
analyses after bariatric surgery are needed and it is possible that 
co-variables such as impaired insulin secretion and diabetes may 
determine plasma MIF levels in this extreme group of metabolically 
deregulated subjects.
Overall, the above studies indicate that whole-body adiposity 
is not a key determinant of circulating MIF and suggest that MIF 
is produced by specific adipose tissue depots during a particular 
period of depot growth (i.e., adipocyte expansion within the depot) 
and resulting adipose tissue inflammation. Of note, circulating 
MIF may also be produced by other tissues and cells in obesity. 
Besides adipose tissue as a possible source of circulating MIF in 
obesity, there are some reports on MIF expression by mononuclear 
cells (MNCs), with reports of increased MIF mRNA expression 
by MNC from obese subjects (26, 27, 29). Although MNC MIF 
expression did not correlate with plasma MIF levels (26), a cor-
relation with BMI was reported in two of these studies (26, 27) and 
weight loss (BMI from 32.5 ± 1.2 to 30.6 ± 1.6 kg/m2) significantly 
reduced MNC MIF mRNA expression (29).
Relationship (Circulating) MiF and insulin 
Resistance
Results from observational studies have shown increased levels of 
circulating MIF in insulin resistant and T2D subjects (Table 2). 
Yabunaka et  al. (47) reported increased serum MIF levels in 
Japanese type 2 diabetic subjects (20.7 ±  1.5 ng/ml) compared 
with healthy control subjects (5.2 ± 0.3 ng/ml); however, there was 
no correlation between MIF and fasting plasma glucose, HbA1c, 
or diabetes duration. Interestingly, BMI was comparable between 
T2D patients and controls in this study (23.9 ± 0.3 kg/m2 in T2D 
vs. 23.8 ±  0.4  kg/m2 in controls) indicating that the observed 
difference was not attributable to a higher BMI in the diabetic 
subjects. (N.B. as the study was conducted in an Asian population 
absolute BMI values are lower than in Caucasian diabetes patients.) 
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Similarly, Yu and colleagues (48) showed increased MIF levels in 
Chinese T2D patients (2.6 ± 0.1 ng/ml) compared with healthy 
controls (2.1 ± 0.1 ng/ml), which again were independent of BMI 
(23.9 ± 0.1 kg/m2 in T2D vs. 22.9 ± 0.3 kg/m2 in controls). In line 
with these findings, Sanchez-Zamora et al. reported increased MIF 
levels (~0.2 vs. ~0.05 ng/ml) in Mexican T2D patients relative to 
healthy controls (49), although BMI for the different groups was 
not stated in this study.
These associations with MIF have also been reported in earlier 
stages of T2D development (impaired glucose tolerance, insulin 
resistance), before overt T2D is present. Herder et al. (50) reported 
increased serum MIF concentrations in German individuals with 
impaired glucose tolerance (median MIF 7.95 vs. 4.97 ng/ml in 
healthy controls) and further increased levels in individuals with 
T2D (median MIF 10.96 ng/ml), suggesting a gradual increase of 
MIF with severity of the disease. In this study, BMI was higher in 
the insulin resistant and T2D subjects than in the healthy controls. 
In line with these results, a positive association between plasma 
MIF levels and insulin resistance was shown in a study in Pima 
Indians (51) and correlations with homeostatic model assessment 
(HOMA; a method used to quantify insulin resistance) (26, 27) 
and β-cell dysfunction (28) have also been reported. Furthermore, 
MIF mRNA expression in freshly isolated subcutaneous abdominal 
adipocytes was found to be negatively associated with donor 
peripheral and hepatic insulin action in another study in Pima 
Indians (43).
In a prospective case-cohort study (52), baseline levels of serum 
MIF were found to be higher in incident T2D cases than in non-
case controls (mean follow-up 10.1 ± 0.1 years, only significant in 
women) and this association between elevated MIF serum levels 
and T2D risk was stronger in obese than in non-obese women. 
Furthermore, this study reported significant associations between 
serum MIF levels in women and MIF genotype rs1007888CC, and 
carriers of this allele had a 1.7-fold increased risk of T2D. A differ-
ent MIF genotype (rs755622GC) was shown to be associated with 
baseline diabetes in men but not in women in a population-based 
cohort study in Turkish subjects, and carriage of the C-allele tended 
to predict new-onset diabetes in this population (53).
MIF has also been implicated in gestational diabetes, with higher 
serum MIF in women with gestational diabetes (11.2 ± 0.75 ng/
ml) than in healthy pregnant controls (5.31 ± 0.64 ng/ml) (54). 
Furthermore, associations between MIF genotype Rs1007888GG 
and gestational diabetes as well as pre-pregnancy obesity and 
family history of diabetes have been reported (55). This specific 
genotype was also found to be twofold more frequent in women 
with metabolic syndrome (55).
Compared with the overweight/obesity studies, there are 
relatively few studies in insulin resistant/T2D subjects, and these 
have been conducted in very specific populations (e.g., Asians, 
Pima Indians). While there were intervention studies (weight loss, 
bariatric surgery) in overweight/obese subjects, no such reports 
exist in the case of T2D. Therefore, conclusions should be drawn 
carefully. Overall, circulating MIF seems to be associated with insu-
lin resistance and overt T2D, and MIF levels rise with the severity 
of disease. This suggests that MIF-inducing processes unrelated to 
obesity/adiposity and adipose tissue expression may contribute to 
circulating MIF levels as overweight/obesity progresses to T2D. 
Inflammatory processes in other tissues or in circulating immune 
cells may be of importance in this respect. The involvement of 
sources of inflammation other than adipose tissue may explain 
that the associations of MIF and metabolic disease (metabolic 
syndrome, insulin resistance, T2D) appear to be independent of 
obesity with increasing complexity of disease (Figure 2).
Relationship MiF and NaFlD
To date, only one study has examined the role of MIF in NALFD 
patients. Akyildiz et  al. (56) investigated the effect of MIF-173 
G/C gene polymorphism in NAFLD and found no difference 
in genotype or C-allele frequency between healthy controls 
(n =  104) and NAFLD patients (n =  91). Furthermore, they 
did not find any differences in genotype or C-allele frequency 
within the NAFLD patient group when subjects were stratified 
for NAFLD score (steatosis/borderline NASH/NASH) or fibrosis 
stage. Immunohistological investigation of MIF expression in liver 
biopsies from the NAFLD patients in this study showed that MIF 
staining was increased in both hepatocytes and MNCs in NASH 
patients compared to those with only steatosis. While hepatocyte 
MIF expression was not associated with fibrosis stage, fibrosis stage 
was significantly higher in presence of MIF staining in MNCs 
and positive MNC MIF staining was associated with a 3.6-fold 
increased risk of fibrosis.
animal Studies
Several studies in genetically engineered mouse models that lack 
the Mif gene have aimed to unravel the role of MIF in both non-
pathological glucose homeostasis and in the obese/insulin resistant 
state. The results of these studies have been summarized in Table 3.
Role of MiF in Non-Pathological glucose 
Homeostasis
Nikolic et  al. (57) demonstrated that Mif-deficient mice (male, 
12  weeks old, diet not specified, C57BL/6 background) have 
impaired insulin signaling (AKT phosphorylation) in liver and adi-
pose tissue. This was reflected in their response to an intraperitoneal 
glucose tolerance test (ipGTT), during which Mif −/− mice had a 
similar insulin response to wild-type mice, but showed impaired 
clearance of glucose. In this experiment, glucocorticoid receptor 
inhibition rescued the observed impairment of insulin signaling in 
liver and adipose tissue, and enhanced glucose-stimulated insulin 
release and glucose clearance during the ipGTT. A second study by 
the same group (58) confirmed that Mif−/− mice (male, 8–12 weeks 
old, diet not specified, C57BL/6 background) show a comparable 
insulin response to an ipGTT to wild-type mice (however, the 
glucose response was not shown in this study). A rationale for these 
observations was provided by results from in vitro experiments (58) 
that showed that conditioned medium containing insulin secreted 
from Mif−/− pancreatic islets had lower activity than conditioned 
medium with insulin produced by wild-type islets, as demonstrated 
by reduced insulin signaling (AKT phosphorylation) and glucose 
uptake in a human liver carcinoma cell line (Hep G2 cells). 
Furthermore, this study revealed that MIF physically interacts and 
binds with insulin in wild-type islets and affects the conformation 
of insulin, reducing the concentration of monomer/dimer insulin 
FiguRe 2 | associations between MiF and obesity are lost with 
increasing disease complexity. In early obesity, circulating MIF levels are 
increased in association with expansion and inflammation of adipose tissue. 
The development of obesity-related co-morbidities is related to elevated MIF 
levels, which rise with increasing severity of disease. In later stages of 
obesity-associated disease, MIF levels appear to be elevated independent of 
obesity and adiposity. Thus, indicating that other sources of inflammation 
such as circulating mononuclear cells, liver inflammation, and vascular 
inflammation may contribute to circulating MIF levels with increasing disease 
complexity.
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and increasing hexamer formation of insulin, which may contribute 
to enabling insulin’s full functionality. These effects were found to 
be independent of MIF’s tautomerase activity.
Serre-Beinier and colleagues (59) investigated the role of MIF 
in carbohydrate homeostasis over time with aging. For this they 
used Mif−/− C57BL/6 mice from a 129/Sv background (diet and 
sex not specified) and examined glucose and insulin tolerance 
over time. Mif−/− mice had lower (13%) body weight at birth, but 
gained weight faster than wild-type mice. By 4  months of age, 
body weights were similar to those of wild-type mice, and at 
12 months of age, they were 17% higher than in wild-type mice. 
While fasting blood glucose remained stable over time in both 
Mif-deficient and wild-type mice, fasting insulin increased over 
time in Mif−/− mice but remained stable in wild-type mice. IpGTTs 
showed that Mif−/− mice cleared glucose more rapidly than wild-
type mice, but insulin levels were higher in the Mif-deficient mice, 
indicating that they required more insulin to achieve this effect. 
At 12 months of age, glucose clearance was impaired relative to 
wild-type mice, with comparable insulin levels. These results are 
in line with findings by Nikolic et al. (57) and Vujicic et al. (58) 
described above, which suggest that insulin produced in absence 
of MIF may have reduced activity/functionality. The response to 
exogenous insulin (during intraperitoneal insulin tolerance tests; 
ipITTs, and euglycemic–hyperinsulinemic clamps) was similar 
between genotypes at 4 and 12 months of age and there were no 
differences in insulin-stimulated AKT phosphorylation in muscle, 
indicating that insulin sensitivity of this peripheral tissue is not 
affected by MIF.
While these studies indicate that MIF may contribute to insulin 
function in non-pathological glucose homeostasis (i.e., in absence 
of obesity or disease), the associations observed in human studies 
indicate that it may have a detrimental role in obesity and the 
development of obesity-associated insulin resistance and T2D, i.e. 
conditions of metabolic stress and disturbed metabolic homeosta-
sis. Several groups have addressed this using experimental models 
of obesity and insulin resistance/T2D.
Role of MiF in (Diet-induced) Obesity and insulin 
Resistance
Several groups have investigated the role of MIF in obesity and 
associated development of insulin resistance/T2D using high-fat diet 
(HFD)-induced rodent models of disease (Table 3). Velickovic and 
colleagues (60) reported higher plasma MIF levels in  fructose-fed 
Wistar rats than in controls (13.6 ± 1.7 vs. 11.0 ± 0.9 ng/ ml), and 
showed that MIF levels correlated with visceral adipose tissue 
mass, consistent with observations made in humans. In line with 
this, Saksida et al. (61) showed that HFD feeding in C57BL/6 mice 
resulted in an obese phenotype, with increased fasting glycemia and 
serum insulin, which was accompanied by increased serum MIF 
Table 3 | MiF in experimental models of obesity and insulin resistance/T2D.
Model Diet Sex effect observed Reference
Mif−/− C57BL/6 mice ns Male Glucose tolerance (ipGTT) is impaired in Mif-deficient mice. (57)
Mif−/− C57BL/6 mice ns Male Insulin secretion after ipGTT is similar in Mif-deficient and wild-
type mice (glucose response is not specified).
(58)
Mif−/− C57BL/6 mice (from 129/Sv 
background)
ns ns Age-dependent impairment of glucose tolerance (ipGTT) in 
Mif-deficient mice.
(59)
Wistar rats Standard diet + 10% 
fructose in drinking water
Male Higher plasma MIF (tendency) in fructose-fed rats than 
controls. Correlation with visceral adipose tissue mass.
(60)
C57BL/6 mice HFD (60% fat) Male Higher plasma MIF on HFD than on control diet. (61)
Mif−/− C57BL/6J mice HFD (45 en% from palm 
oil)
Male Mif deficiency protects against development insulin resistance: 
lower ipGTT and ipITT.
(62)
Ldlr−/−Mif−/− mice (C57BL/6 background) Chow Male Mif deficiency protects against development insulin resistance: 
fasting plasma glucose and insulin lower, improved ipGTT, 
ipITT, and euglycemic clamp.
(9)
Mif−/− C57BL/6 mice HFD (60 en% fat) ns Mif deficiency increases fasting glucose and impairs glucose 
tolerance (ipGTT).
(63)
Mif−/− C57BL/6 mice (from Mif−/+ Balb/c 
background)
HFD (60% fat) Male Mif deficiency does not affect development of glucose 
intolerance (ipGTT) or plasma insulin levels.
(64)
STZ- and L-NAME-induced impaired 
glucose tolerance in Sprague-Dawley rats
Chow ns Plasma MIF levels higher in impaired glucose tolerance rats 
than in controls.
(48)
STZ-induced T2D in Mif−/− Balb/c mice ns Female Mif-deficient mice have lower STZ-induced blood glucose and 
better glucose tolerance (OGTT).
(49)
STZ-induced T2D in ICR mice + MIF 
antagonist (CPSI-1306)
ns Female MIF antagonism reduced STZ-induced blood glucose levels.
C57BLKS/J db/db mice + MIF inhibitor 
(ISO-1)
Chow Male MIF inhibition normalized hyperglycemia and improved 
impaired glucose tolerance (ipGTT).
(65)
ns, not specified.
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levels (~7 ng/ml compared with ~0 ng/ml in control diet-fed mice). 
This study also showed that Mif mRNA expression in pancreatic 
islets was increased in HFD-fed mice. Furthermore, they showed 
that in wild-type pancreatic islets, palmitic acid (a saturated fatty acid 
which is present in human diets as well as in experimental HFDs) 
induces MIF production and apoptosis, while pancreatic islets from 
Mif-deficient mice were entirely resistant to palmitic acid-induced 
apoptosis, which may be of importance in β-cell apoptosis in late-
stage obesity-associated T2D.
Finucane and colleagues (62) also described protective effects 
of Mif deficiency in HFD-induced obesity/insulin resistance. In 
this study, Mif−/− mice (male, 8–9  weeks old, C57BL/6J back-
ground) were fed a palm oil based (rich in palmitic acid) HFD 
(45 kcal% fat) for 16 weeks. Mif deficiency reduced HFD-induced 
body weight gain and fat mass and improved the response to 
ipGTT and ipITT. Glucose clearance during the ipGTT was 
improved compared with wild-type mice, with a reduced insulin 
response and similarly, the Mif−/− mice showed a more efficient 
glucose clearance in the ipITT. Together these glucose and insulin 
tolerance tests show that the response to both endogenous insulin 
(produced during ipGTT) and exogenous insulin (injected in 
ipITT) is improved in absence of MIF, thus suggesting an improve-
ment in peripheral insulin signaling in obese Mif−/− mice. These 
effects were also observed when mice were weight-matched to 
exclude effects of body weight differences, suggesting that Mif 
deficiency improves insulin signaling in peripheral tissues, such 
as white adipose tissue.
Support for this notion comes from studies that analyzed the 
effects of MIF on insulin signaling in adipose tissue. Finucane et al. 
(62) further showed that in wild-type mice, obesity increased MIF 
protein expression in the epididymal adipose tissue, for which the 
stromal vascular fraction rather than the adipocyte fraction was the 
primary cellular source. Mif−/− mice were found to have reduced 
adipose tissue inflammation (reduced M1 macrophage infiltration 
and reduced ex vivo cytokine secretion) and this was accompanied 
by improved adipose tissue insulin signaling as demonstrated by 
increased insulin-stimulated AKT phosphorylation and Glut4 
expression in vivo, as well as increased insulin-stimulated glucose 
uptake into adipose tissue explants. Similarly, Verschuren et al. (9) 
used the hyperlipidemic Ldlr−/− background to induce obesity and 
insulin resistance (male mice up to 52 weeks old, chow, C57BL/6 
background) and showed that Mif deficiency protects against the 
development of insulin resistance. Mif-deficient mice had lower 
fasting glucose and insulin levels and showed improved glucose 
tolerance (assessed by ipGTT, with comparable insulin levels dur-
ing the test) and improved insulin sensitivity (assessed by ipITT). 
Furthermore, a hyperinsulinemic–euglycemic clamp showed that 
insulin resistance was reduced in Mif-deficient mice. In line with 
the findings by Finucane et al. (62), analysis of adipose tissue in this 
study showed improvement of peripheral insulin signaling. This 
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study also revealed improvements in adipose tissue inflammation 
in absence of MIF, with smaller adipocytes, reduced macrophage 
infiltration and crown-like structure formation and a lower 
M1/M2 macrophage ratio. This was accompanied by improved 
insulin signaling in adipose tissue (increased insulin-stimulated 
Pi3-Kinase activity and AKT phosphorylation), which further 
corroborates the observed improvements in glucose handling and 
insulin sensitivity. In both these studies, Mif deficiency improved 
the inflammatory milieu in adipose tissue and resulted in improve-
ment of insulin signaling.
While above studies used HFDs with a moderate fat content 
(translational to the human situation), two studies that used diets 
with a supraphysiological fat content (60 kcal%), made different 
observations; Heinrichs et al. (63) reported that Mif deficiency 
in HFD-fed C57BL/6 mice (age and sex not specified) promotes 
weight gain and has detrimental effects on glucose tolerance 
(impaired glucose clearance during ipGTT). Remarkably, adipose 
tissue inflammation was reduced in absence of Mif in this study, 
in line with observations in the more physiological diet-induced 
obesity studies. A study by Conine and co-workers (64) showed 
no difference between Mif−/− mice (male, 6–8 weeks old, C57BL/6 
mice from Mif−/+ Balb/c background) and wild-type mice after 
15 weeks of HFD feeding. In this study, body weight gain and 
adipose tissue inflammation were similar between genotypes, and 
there was no difference in glucose intolerance (assessed by ipGTT) 
or fasting blood glucose and insulin levels.
Role of MiF in (STZ-induced) Diabetes
Others have used streptozocin (STZ; a toxic glucose analog 
that preferentially accumulates in pancreatic beta cells but that 
can also be harmful to other tissues) to induce a (pre-)diabetic 
phenotype (severity depends on STZ dosage and regimen). Yu 
et al. (48) showed that plasma MIF levels were higher in a pre-
diabetic rat model of impaired glucose tolerance (HFD-fed and 
STZ- and L-NAME-treated Sprague-Dawley rats) than in chow-
fed controls (32.5 ± 1.9 vs. 24.8 ± 1.6 ng/ml). Sanchez-Zamora 
and co-workers (49) showed that Mif deficiency in Balb/c mice 
(female, age and diet not specified) lowered STZ-induced blood 
glucose levels and improved glucose tolerance in an oral glucose 
tolerance test (OGTT) without affecting insulin production by 
pancreatic β-cells. Similarly, MIF antagonism (with small molecule 
inhibitor CPSI-1306) reduced STZ-induced blood glucose levels in 
ICR outbred mice in the same study (49). Together, these studies 
in STZ-induced diabetes suggest an improvement of peripheral 
insulin sensitivity and/or more active insulin in Mif-deficient mice. 
The latter, however, would contradict findings by Nikolic et al. (57) 
and Vujicic et al. (58) discussed above.
Overall, these STZ studies lend further support to the notion 
that Mif deficiency protects from (pre)diabetes and are thus in line 
with most of the observations made in diet-induced models of 
obesity and metabolic disease. While in normal physiology, MIFs 
effects in glucose homeostasis were found to be independent of 
MIFs tautomerase activity (58), results from a study by Wang et al. 
(65) suggest that this activity may play a role under pathophysi-
ological conditions. The authors showed that in diabetic db/db 
mice (male, 8 weeks old, chow, C57BLKS/J background), which 
have an autosomal recessive mutation in the leptin receptor, treat-
ment with the MIF tautomerase activity inhibitor ISO-1 reduced 
fasting glucose levels to those observed in non-diabetic controls 
(db/m mice). These effects were further supported by results from 
an ipGTT, which revealed significant improvement in glucose 
handling in ISO-1 treated mice. In the lean, non-diabetic control 
mice, ISO-1 treatment did not affect fasting blood glucose levels 
or ipGTT responses, consistent with the discussed observations 
made by Vujijic et al. (58).
Altogether, these studies indicate that while MIF seems to 
have a function for insulin conformation and functionality in 
non-pathological glucose homeostasis, its role is less clear when 
metabolic stress and pathological processes come into play. Under 
these conditions, Mif deficiency appears to be protective against 
white adipose tissue inflammation and may improve glucose 
metabolism and peripheral insulin resistance although results are 
partly conflicting. An important explanation for these discrepan-
cies is likely to be the choice of rodent model in combination with 
the experimental conditions employed. Inbred mouse strains are 
known to differ greatly in their susceptibility to obesity as well as 
in glucose metabolism and insulin resistance (66–68). Differences 
in the genetic background of knockout mice (as well as successful-
ness of backcrossing onto a different strain) are therefore likely 
to have a large impact on study outcomes. A second factor that 
may influence study results is the choice of diet (i.e., percentage 
of fat, type of fat, palmitic acid content) and the age that mice 
are started on this dietary treatment [for instance, older Ldlr−/− 
mice show a more aggravated disease phenotype in response to 
HFD feeding than younger mice (69)]. Although information on 
the mouse strain and dietary conditions used are critical for the 
interpretation and comparison of different studies, they are often 
inadequately described. Overall, the prevailing finding is that Mif 
deficiency is protective in insulin resistance, glucose tolerance, and 
STZ-induced diabetes, and reduced adipose tissue inflammation 
and improved insulin signaling in adipose tissue may play a role in 
these beneficial effects, in line with observations made in human 
studies. Besides driving the development of insulin resistance and 
T2D in obesity, metabolic inflammation is also believed to drive 
the development of NAFLD (Figure 1).
Role of MiF in Non-alcoholic Fatty liver Disease
Several studies provide indication that MIF may also play a role 
in the development of hepatic steatosis, inflammation and fibrosis 
(Table 4).  Finucane and colleagues (62) showed that Mif deficiency 
alleviates HFD-induced hepatic steatosis (male, 8–9  weeks old, 
16 weeks HFD 45 kcal% fat from palm oil, C57BL/6J background). 
In Mif−/− mice, liver weight was reduced, and hepatic triglyceride 
content (as well as histologically observed steatosis) was reduced. 
Mif-deficient mice also had lower plasma alanine transaminase 
(ALAT) levels. Hepatic gene expression analyses revealed that 
lipogenic gene expression (i.e., Cd36, Dgat-1, Fasn, Srebp1-c, Pgc-a1, 
Lpl, Ppary) was significantly lower in absence of MIF, providing a 
possible rationale for the observed reduction in hepatic steatosis. 
In line with these results, Heinrichs et  al. (63) observed that 
hepatic steatosis was reduced in absence of MIF in both HFD-fed 
(60  kcal% fat, 16  weeks) and methionine and choline-deficient 
(MCD) diet-fed (8 weeks) Mif−/− mice (sex and age not specified, 
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C57BL/6 background). In the HFD-fed mice, Mif deficiency 
increased liver weight while liver damage markers ALAT and 
aspartate transaminase (ASAT) were slightly reduced. The observed 
reduction in hepatic steatosis (analyzed by histological Oil Red O 
staining and biochemical measurement of hepatic triglycerides) was 
accompanied by increased lipogenic gene expression (i.e., transcrip-
tion factors Lxra and Srebp-1, and enzymes Acc, Fas, Dgat1, Dgat2), 
which was also observed in the MCD diet-fed mice. Furthermore, 
HFD-feeding resulted in increased hepatic inflammatory cell infil-
tration (1.6-fold increase in F4/80+ macrophages) in Mif−/− mice, 
which were skewed toward a M2 polarization. Mechanistic in vitro 
experiments in oleic acid/IL-β stimulated mouse hepatoma cells 
Hepa1-6 and primary murine hepatocytes showed that recombi-
nant MIF reduced hepatocyte lipid content through a CD74 and 
AMPK-mediated pathway. In contrast to the above studies, Conine 
et al. (64) observed no difference in HFD-induced (60 kcal% fat) 
hepatic lipid accumulation in presence or absence of Mif (male, 
6–8 weeks old, C57BL/6 mice from Mif−/+ Balb/c background). It is 
not clear whether absence of phenotypical differences in this study 
may be related to the relatively young age of the mice at the start 
of the study, the extreme (supraphysiological) dietary fat content 
or the genetic background of the mice.
While the above studies focused mainly on the lipid accumula-
tion that is observed in NAFLD, others have investigated the role of 
MIF in the development of hepatic fibrosis, a characteristic of pro-
gressive NASH. Barnes and co-workers (70) studied effects of MIF 
in chemically induced liver fibrosis (male and female, 10–12 weeks 
old, C57BL/6 Mif−/− mice). In wild-type mice, a single dose of 
CCl4-induced mRNA expression of Mif and its cognate receptor 
Cd74 (peaking between 4 and 8 h and resolving by 18 h), which 
was also observed in plasma with MIF protein levels increased as 
early as 2 h after injection (indicating a release of preformed pools 
of MIF). Circulating ALAT and ASAT were similarly increased in 
Mif−/− and wild-type mice indicating comparative liver damage 
between genotypes. Assessment of hepatic stellate cell activation 
upon chronic CCl4 treatment (2 i.p. injections per week for 5 weeks) 
revealed increased mRNA expression of Acta2 (α-SMA) and Col1a1 
(Collagen type I, alpha 1) in male Mif−/− mice compared with 
Table 4 | MiF in experimental models of NaFlD/liver fibrosis.
Model Diet Sex effect observed Reference
Mif−/− C57BL/6J mice HFD (45 en% from palm 
oil)
Male Plasma ALT lower in Mif-deficient mice. Liver triglycerides, 
lipogenic gene expression, and pNFκB reduced in  
Mif-deficient mice.
(62)
Mif−/− C57BL/6 mice HFD (60 en% fat) ns Mif deficiency increases hepatic steatosis and hepatic 
immune-cell infiltration
(63)
MCD diet ns Liver triglycerides increased in Mif-deficient mice.
Mif−/− C57BL/6 mice (from Mif−/+ Balb/c 
background)
HFD (60% fat) Male Mif deficiency does not affect hepatic lipid accumulation. (64)
Mif−/− C57BL/6 mice + CCl4 Chow (Teklad) Male and 
female
Liver fibrosis in Mif-deficient mice similar to wild-type. (70)
Mif−/− C57BL/6 mice + CCl4 or + TAA ns ns Liver fibrosis more severe in Mif-deficient mice (both CCL4- 
and TAA-induced).
(71)
C57BL/6 mice + CCl4 + rMIF ns ns Treatment with rMIF reduced hepatic stellate cell activation 
and repressed expression of fibrosis-relevant genes.
ns, not specified.
wild-type, while expression of these genes was reduced in female 
Mif−/− mice compared with wild-type mice. Despite these effects of 
Mif deficiency on hepatic stellate cell activation, hepatic collagen 
deposition (assessed by quantification of Sirius Red staining and 
hydroxyproline measurement) was comparable to wild-type mice 
in both male and female Mif−/− mice. Authors then continued their 
studies in female mice only, to investigate a potential role of MIF 
on the progression of fibrosis via the regulation of extracellular 
matrix (ECM) degradation. They observed reduced infiltration of 
restorative macrophages in Mif−/− mice, which was accompanied 
by reduced expression (mRNA, protein, and enzymatic activity) 
of the ECM-degrading metalloproteinase MMP13, suggesting a 
possible proresolution role for MIF during fibrosis.
Heinrichs and colleagues (71) also investigated the effects of 
Mif deficiency (age and sex not specified, C57BL/6 Mif−/− mice) 
in two different models of chemically induced liver fibrosis. In this 
study, hepatic fibrosis (assessed histologically and by hydroxyproline 
measurement) was increased in absence of MIF in both CCl4- and 
TAA-induced liver fibrosis. In line with this, Mif-deficient mice had 
increased mRNA expression of Col1a1, Timp1, Mmp2, and Tgfb1, as 
well as increased α-SMA protein expression. FACS analysis revealed 
no differences between genotypes in immune-cell subset infiltration, 
suggesting that differences in fibrosis development may be explained 
by effects on hepatic stellate cell activation rather than by effects on 
the intrahepatic immune response. In vitro studies in murine hepatic 
stellate cells showed that treatment with recombinant MIF inhibited 
PDGF-induced hepatic stellate cell activation, which was found to 
be mediated through CD74 and AMPK signaling. In line with these 
in vitro results, follow-up in vivo studies showed that CCl4-induced 
hepatic fibrosis was increased in Cd74−/− mice. Deficiency of Cxcr4, 
however, another MIF receptor expressed by hepatic stellate cells, 
did not affect fibrosis development. Therapeutic application of 
recombinant MIF in CCl4-treated wild-type mice reduced hepatic 
stellate cell activation and repressed expression of fibrosis-relevant 
genes. However, the effects of this recombinant MIF treatment on 
fibrosis development are not mentioned.
Overall, very few studies to date have investigated the effects of 
MIF in the development of hepatic co-morbidities. MIF appears 
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to have detrimental effects in HFD-induced hepatic lipid accu-
mulation through effects on lipogenic gene expression, providing 
further support for the notion that MIF may indeed not only have 
pro-inflammatory effects but may also be linked to metabolism. 
In chemically-induced liver fibrosis, it seems that MIF may have 
protective effects, possibly through an effect on the resolution of 
fibrosis. However, results from a clinical study in NAFLD patients 
indicate the opposite, showing that increased MIF expression in 
liver is associated with increased risk of fibrosis. This discrepancy 
may be explained by differences in disease etiology in chemically 
induced liver damage used in the experimental disease models, 
compared with the metabolically induced liver damage that is 
typical for human NAFLD development.
Conclusion and Future Directions
In early obesity, circulating MIF levels are increased in association 
with expansion and inflammation of adipose tissue. The develop-
ment of insulin resistance and T2D in obesity is related to elevated 
MIF levels, which rise with increasing severity of disease. In 
later stages of obesity-associated T2D, MIF levels appear to be 
elevated independent of obesity and adiposity, indicating that with 
increasing disease complexity, other sources of inflammation may 
contribute to circulating MIF levels.
Mechanistic studies in experimental models of disease have 
shown that MIF contributes to insulin function in non-pathological 
glucose homeostasis (i.e., in absence of obesity or disease) but its 
role is less clear when metabolic stress and pathological processes 
come into play. Under these conditions, Mif deficiency appears to 
be protective against adipose tissue inflammation and may improve 
insulin resistance and T2D in both HFD- and STZ-induced 
models. Furthermore, there are some first indications that MIF 
may contribute to development of diet-induced hepatic steatosis in 
NAFLD, while observations in advanced liver disease are conflict-
ing, describing both pro- and anti-fibrotic effects of MIF.
To fully understand the intricacies of MIFs contribution 
to obesity-related disease development, future work is needed 
to decipher temporal (non-pathological – early disease – 
advanced complex disease) and spatial (tissue-specific) effects 
of MIF, as well as interorgan crosstalk that may be mediated 
by circulating MIF. For the interpretation of such studies, it 
is of paramount importance that they would be performed 
in translational, physiological (diet-induced) models under 
well-described experimental conditions. In addition, future 
studies assessing the complex interplay between metabolic and 
inflammatory balances will greatly enhance our understanding 
of the development of obesity-related diseases, and the role 
of MIF therein. Although most published data on MIF point 
toward a detrimental role in advanced stages of disease, the 
potential protective effects of this mediator under certain 
conditions deserve further investigation.
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